As expected, HAPD significantly inhibited CRC tumorigenicity and reduced CRC liver metastasis and lung metastasis, indicating that these duplex genome-editing nanoparticles have a potential application value for the treatment of tumors carrying APC and KRAS mutations [226]. The gene discussed is KRAS; the disease is colorectal carcinoma.